Nektar Presents Positive Preclinical Data On Oral, Peripherally-Acting Kappa Agonist Molecules At 2014 American Academy Of Pain Management Meeting

By: via Benzinga
Nektar Therapeutics (NASDAQ: NKTR) today announced results from preclinical studies characterizing the analgesic profiles of a series of ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.